Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active me...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Perrone, Emanuele, Lopez, Salvatore, Zeybek, Burak, Bellone, Stefania, Bonazzoli, Elena, Pelligra, Silvia, Zammataro, Luca, Manzano, Aranzazu, Manara, Paola, Bianchi, Anna, Buza, Natalia, Tymon-Rosario, Joan, Altwerger, Gary, Han, Chanhee, Menderes, Gulden, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Hui, Pei, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2020
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7028697/
https://ncbi.nlm.nih.gov/pubmed/32117765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00118
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia